In conjunction with the acquisition Vitrolife also preannounced its Q2’21 figures. Sales came in at SEK 382m, corresponding CER growth of 94% (8% CER growth vs. Q2’19) and adj. EBITDA was SEK 148m for a margin of 39%. There is a conf. call at 10.00 CET. Dial-in: SEK: +46 8 566 184 67 INT: +44 2071 928338
Aktuellt
SENASTE
